ResearcherCase Comprehensive Cancer CenterNo recent work listed

Stanton L. Gerson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3106-2549; OpenAlex author ID A5019470085; NIH RePORTER profile ID 6573086. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 1
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 grant

Papers 1

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. Co-author DOI 10.1038/srep17066 ↗

Grants 1

Cognitive Impairment, Multimorbidity, and end-of-life care in older cancer patients P30CA043703 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gaurab Chakrabarti · 1 shared paper, 2015 · strength 0.04
- Paper Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-l… DOI 10.1038/srep17066 ↗
Molly A. Silvers · 1 shared paper, 2015 · strength 0.04
- Paper Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-l… DOI 10.1038/srep17066 ↗
Zachary Moore · 1 shared paper, 2015 · strength 0.04
- Paper Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-l… DOI 10.1038/srep17066 ↗
David A. Boothman · 1 shared paper, 2015 · strength 0.04
- Paper Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-l… DOI 10.1038/srep17066 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.